- Drug pipelines, Patents, Clinical trials

Overview

Basic Info

Introduction

Shanghai Xianshang Pharmaceutical Technology Co., Ltd. operates as a subsidiary under the larger umbrella of Xiansheng Pharmaceuticals. This entity was established in September 2022 and primarily concentrates on the development in areas such as oncology, neurology, autoimmune diseases, and anti-infective treatments.

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

Trispecific antibody

Fusion protein

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Immune System Diseases	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1
Trispecific antibody	1
Fusion protein	1

Top 5 Target	Count

BCMA x CD3 x GPRC5D(B-cell maturation protein x T cell surface glycoprotein CD3 x G-protein coupled receptor family C group 5member D)	1
USP1(ubiquitin specific peptidase 1)	1
IL-15 x PDL1(Interleukin-15 x Programmed death-ligand 1)	1

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.

Start Date30 May 2024

Sponsor / Collaborator

Jiangsu Simcere Pharmaceutical Co., Ltd.

[+1]

NCT06331559 / RecruitingPhase 1

A Phase I First-in-human, Open-label Trial to Investigate the Safety, Pharmacokinetics and Antitumor Activity of SIM0501 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

This is an open-label, multicenter Phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0501 in participants with advanced solid tumors. The trial consists two parts, Part 1 for SIM0501 monotherapy and Part 2 for SIM0501 in combination with olaparib. In both parts, SIM0501 with/without olaparib will be administered until disease progression or the investigator determines that continuation of the study drug would not benefit, or there is intolerable toxicity, or the participant or legal representative voluntarily requests withdrawal, or the trial is terminated.

Start Date19 Mar 2024

Sponsor / Collaborator

Jiangsu Simcere Pharmaceutical Co., Ltd.

[+1]

CTR20240500 / RecruitingPhase 1

评价SIM0501单药治疗和联合治疗在晚期实体瘤受试者中的安全性、药代动力学和抗肿瘤活性的首次人体、开放性I期研究

[Translation] First-in-human, open-label Phase I study to evaluate the safety, pharmacokinetics and anti-tumor activity of SIM0501 monotherapy and combination therapy in subjects with advanced solid tumors

主要目的：第1部分：评价SIM0501单药治疗的安全性和耐受性，并确定最大耐受剂量1（maximum tolerated dose 1, MTD1）和/或推荐剂量1（recommended dose 1, RD1）；第2部分：评价SIM0501联合奥拉帕利的安全性和耐受性，并确定MTD2和/或RD2；次要目的：进一步评价SIM0501单药治疗和与奥拉帕利联合治疗的安全性和耐受性特征；评价SIM0501单药治疗和与奥拉帕利联合治疗的药代动力学（pharmacokinetics, PK）特征；评价SIM0501单药治疗和与奥拉帕利联合治疗的初步抗肿瘤活性。

[Translation]

main purpose: Part 1: Evaluate the safety and tolerability of SIM0501 monotherapy and determine the maximum tolerated dose 1 (MTD1) and/or recommended dose 1 (RD1); Part 2: Evaluate the safety and tolerability of SIM0501 combined with olaparib, and determine MTD2 and/or RD2; Secondary purpose: To further evaluate the safety and tolerability characteristics of SIM0501 as monotherapy and in combination with olaparib; Evaluate the pharmacokinetics (PK) characteristics of SIM0501 as monotherapy and in combination with olaparib; To evaluate the preliminary anti-tumor activity of SIM0501 as monotherapy and in combination with olaparib.

Start Date13 Mar 2024

Sponsor / Collaborator

Shanghai Xianxiang Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with

Login to view more data

0 Patents (Medical) associated with

Login to view more data

100 Deals associated with

Login to view more data

100 Translational Medicine associated with

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

2

IND Approval

Phase 1 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SIM-237 ( IL-15 x PDL1 )	Non-Muscle Invasive Bladder Neoplasms More	Phase 1
SIM0348 ( CD112R x TIGIT )	Solid tumor More	IND Approval
Sevacizumab ( VEGF x VEGF-A )	Solid tumor More	IND Approval
SIM-0500 ( BCMA x CD3 x GPRC5D )	-	IND Application
SIM-0501 ( USP1 )	-	IND Application